Advertisement
Singapore markets open in 2 minutes
  • Straits Times Index

    3,489.57
    +1.66 (+0.05%)
     
  • S&P 500

    5,588.27
    -78.93 (-1.39%)
     
  • Dow

    41,198.08
    +243.60 (+0.59%)
     
  • Nasdaq

    17,996.92
    -512.42 (-2.77%)
     
  • Bitcoin USD

    64,502.83
    -969.45 (-1.48%)
     
  • CMC Crypto 200

    1,336.28
    -6.05 (-0.45%)
     
  • FTSE 100

    8,187.46
    +22.56 (+0.28%)
     
  • Gold

    2,463.00
    +3.10 (+0.13%)
     
  • Crude Oil

    83.17
    +0.32 (+0.39%)
     
  • 10-Yr Bond

    4.1460
    -0.0210 (-0.50%)
     
  • Nikkei

    40,197.12
    -900.57 (-2.19%)
     
  • Hang Seng

    17,739.41
    +11.43 (+0.06%)
     
  • FTSE Bursa Malaysia

    1,633.54
    +7.58 (+0.47%)
     
  • Jakarta Composite Index

    7,224.22
    -7,224.29 (-50.00%)
     
  • PSE Index

    6,687.71
    +20.62 (+0.31%)
     

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors

Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future.